$CBAY: I personally like the fact that it is trading well under cash, it has been beaten down due to postponing results from Q4 2015 to Q1 2016, due to increasing number of patients to 13 from 8, and the fact that the lesinurad adcom is in late dec (dec 29) and people think that lesinurad will be approved. I personally am not so sure, but the 10-4 positive adcom did make people think that IMO. Should be interesting going forward. DYODD!!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.